Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer

Delta-like ligand 4 (Dll4) is a Notch ligand that is predominantly expressed in the endothelium. Evidence from xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth factor therapy. The aims of this study were to characterize the expression of Dll4 in bre...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The American journal of pathology Ročník 176; číslo 4; s. 2019
Hlavní autori: Jubb, Adrian M, Soilleux, Elizabeth J, Turley, Helen, Steers, Graham, Parker, Andrew, Low, Irene, Blades, Jennifer, Li, Ji-Liang, Allen, Paul, Leek, Russell, Noguera-Troise, Irene, Gatter, Kevin C, Thurston, Gavin, Harris, Adrian L
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.04.2010
Predmet:
Aged
Breast - pathology
Breast Neoplasms - pathology
Cell Line, Tumor
Disease-Free Survival
Endothelium - pathology
Female
Hemangiosarcoma - pathology
Humans
Immunohistochemistry
In Situ Hybridization
Inflammation
Intercellular Signaling Peptides and Proteins - biosynthesis
Intercellular Signaling Peptides and Proteins - physiology
Middle Aged
Prognosis
ISSN:1525-2191, 1525-2191
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Delta-like ligand 4 (Dll4) is a Notch ligand that is predominantly expressed in the endothelium. Evidence from xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth factor therapy. The aims of this study were to characterize the expression of Dll4 in breast cancer and assess whether it is associated with inflammatory markers and prognosis. We examined 296 breast adenocarcinomas and 38 ductal carcinoma in situ tissues that were represented in tissue microarrays. Additional whole sections representing 10 breast adenocarcinomas, 10 normal breast tissues, and 16 angiosarcomas were included. Immunohistochemistry was then performed by using validated antibodies against Dll4, CD68, CD14, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), CD123, neutrophil elastase, CD31, and carbonic anhydrase 9. Dll4 was selectively expressed by intratumoral endothelial cells in 73% to 100% of breast adenocarcinomas, 18% of in situ ductal carcinomas, and all lactating breast cases, but not normal nonlactating breast. High intensity of endothelial Dll4 expression was a statistically significant adverse prognostic factor in univariate (P = 0.002 and P = 0.01) and multivariate analyses (P = 0.03 and P = 0.04) of overall survival and relapse-free survival, respectively. Among the inflammatory markers, only CD68 and DC-SIGN were significant prognostic factors in univariate (but not multivariate) analyses of overall survival (P = 0.01 and 0.002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1525-2191
1525-2191
DOI:10.2353/ajpath.2010.090908